Novo Nordisk's UBT251 Phase II clinical data in China is impressive, with a weight loss effect of nearly 20%.

Novo Nordisk’s experimental weight loss drug UBT251 achieved significant weight loss results in phase 2 clinical trials in China, providing strong support for the company to find new growth engines in the highly competitive weight loss drug market.

According to a report from Novo Nordisk's Chinese partner, United Laboratories, obese and overweight patients in China who took the drug for 24 weeks saw a maximum weight reduction of 19.7%, while in comparison, patients taking the placebo lost an average of only 2% in weight.

Novo Nordisk’s head of R&D, Martin Holst Lange, said in a statement that the company was “very encouraged” by the data from this Chinese trial. Based on these positive midterm results, United Laboratories will launch phase 3 clinical trials in China, while Novo Nordisk plans to release the top-line results from its ongoing global early trials in 2027.

Despite the impressive data from the new drug, Novo Nordisk’s recent performance in the capital markets remains under pressure. On Tuesday, the company’s share price fell as much as 4.4% during the day due to negative news about its next-generation weight loss drug Cagrisema and multiple analysts downgrading their ratings. Over the past year, the company’s share price has dropped by more than 60%.

Triple Agonist Shows Greater Potential

The clinical data released this time reveals the potential of multi-target drugs in the weight loss field. A total of 205 patients participated in this phase 2 trial; they were randomly assigned to receive doses of 2mg, 4mg, 6mg of the drug or a placebo. The current trial results are based on the estimated effect if all patients stick to their medication schedule, with no specific details provided yet about whether any patients stopped treatment.

UBT251 is a triple agonist that can simultaneously mimic three hormones involved in metabolism: GLP-1, GIP, and glucagon. This multi-action mechanism suggests it may be more effective than Novo Nordisk’s current blockbuster weight loss drug Wegovy, which only targets GLP-1.

Multi-billion Dollar Bet

This promising drug is a major external investment by Novo Nordisk to maintain its dominance in the obesity market. Last year, the Danish pharmaceutical company paid a $200 million upfront fee to acquire the rights to develop UBT251 outside China.

As clinical progress continues and potential commercialization approaches, the total value of this licensing deal could reach up to $2 billion. Amid calls from investors for the company to adjust its strategy and respond to recent setbacks in R&D, the progress of UBT251 is expected to boost market confidence in Novo Nordisk’s pipeline.

Risk Warning and DisclaimerThe market involves risk, investment requires caution. This article does not constitute personal investment advice and has not taken into account the specific investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their particular circumstances. Investments made on this basis are at your own risk.